GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Valuation Rank

Vivesto AB (Vivesto AB) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Vivesto AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivesto AB (Vivesto AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Valuation Rank
Comparable Companies
OSTO:ERMA XSAT:PMED XSAT:ODI XSAT:DICOT OSTO:NANEXA OSTO:NEWBRY OSTO:KLAR OSTO:RLS OSTO:MOB OSTO:EMPLI ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
VIVE:Sweden OMAX:Germany
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Website
https://www.vivesto.com
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.